Skip to main content
SpringerLink
Log in

Surface Epithelial Tumors: Clinical Introduction

  • Chapter
  • First Online:
Diagnostic Pathology of Ovarian Tumors

Abstract

This chapter describes the important clinical aspects of epithelial ovarian neoplasms. The greatest risk factors for developing ovarian cancer are BRCA1 or BRCA2mutations and Lynch syndrome. The best method for obtaining a definitive diagnosis is surgical. Accurate intraoperative frozen section assessment is crucial; these frozen section results often determine the extent of the surgical procedure. If the frozen section result is malignancy, then a comprehensive staging procedure is required. This chapter outlines the most common diagnoses made on frozen section and includes key questions to be addressed by the pathologist at the time of frozen section assessment for masses confined to the adnexa(e) or with presumed metastasis. Since the decision whether or not to give adjuvant chemotherapy is directly related to stage at diagnosis and the grade of the tumor, this chapter provides pathologists with a list of key questions to assist in this determination.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  3. Antoniou A, Pharaoh PDP, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.

    Article  PubMed  CAS  Google Scholar 

  4. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26(1):20–5.

    Article  PubMed  Google Scholar 

  5. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20(2):463–6.

    Article  PubMed  CAS  Google Scholar 

  6. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283(17):2260–5.

    Article  PubMed  CAS  Google Scholar 

  7. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 1998;58:4023–37.

    PubMed  CAS  Google Scholar 

  8. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee E. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res. 1999;59:3547–51.

    PubMed  CAS  Google Scholar 

  9. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393–402.

    Article  PubMed  CAS  Google Scholar 

  10. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13.

    Article  PubMed  CAS  Google Scholar 

  11. Vasen HFA, Watson P, Mecklin J, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch Syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology. 1999;116:1453–6.

    Article  PubMed  CAS  Google Scholar 

  12. Leitao Jr MM, Chi DS. Fertility-sparing options for patients with gynecologic malignancies. Oncologist. 2005;10:613–22.

    Article  PubMed  Google Scholar 

  13. Leitao Jr MM, Chi DS. Operative management of primary epithelial ovarian cancer. Curr Oncol Rep. 2007;9:478–84.

    Article  PubMed  CAS  Google Scholar 

  14. Winter III WE, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol. 2002;100:671–6.

    Article  PubMed  Google Scholar 

  15. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol. 2002;86:34–7.

    Article  PubMed  Google Scholar 

  16. Geomini P, Bremer G, Kruitwagen R, Mol BWJ. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol. 2005;96:1–9.

    Article  PubMed  Google Scholar 

  17. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006;103:559–64.

    Article  PubMed  CAS  Google Scholar 

  18. FIGO. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3–4.

    Article  Google Scholar 

  19. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07–6215, Bethesda, MD, 2007.

    Google Scholar 

  20. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.

    Article  PubMed  CAS  Google Scholar 

  21. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–5.

    Article  PubMed  CAS  Google Scholar 

  22. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an Intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–7.

    PubMed  CAS  Google Scholar 

  23. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    Article  PubMed  CAS  Google Scholar 

  24. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006;102:285–91.

    Article  PubMed  Google Scholar 

  25. Hess V, A’Hern RA, Nasiri N, King DM, Blake PR, Barton DPJ, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040–4.

    Article  PubMed  CAS  Google Scholar 

  26. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239–51.

    Article  PubMed  CAS  Google Scholar 

  27. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–51.

    Article  PubMed  CAS  Google Scholar 

  28. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235–44.

    Article  PubMed  CAS  Google Scholar 

  29. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512–19.

    Article  PubMed  CAS  Google Scholar 

  30. Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer. 2008;99(12):2020–8.

    Article  PubMed  CAS  Google Scholar 

  31. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Köbel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433.

    Article  PubMed  Google Scholar 

  32. Swenerton KD, Santos JL, Gilks CB, Köbel M, Hoskins PJ, Wong F, et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol. 2010;22(2):341–7 [Epub ahead of print].

    Article  PubMed  Google Scholar 

  33. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 1990;36:207–11.

    Article  PubMed  CAS  Google Scholar 

  34. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389–93.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Gynecology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Mario M. Leitao Jr. M.D.

  2. Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Katherine M. Bell-McGuinn M.D., Ph.D.

Authors
  1. Katherine M. Bell-McGuinn M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mario M. Leitao Jr. M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. Pathology, Memorial Sloan-Kettering Cancer Center, York Ave. 1275, NEW YORK, 10021, New York, USA

    Robert A. Soslow

  2. SUNY Stony Brook, Department of Pathology, Stony Brook Univ Medical Center, Hospital Level 2, Room 766, Stony Brook, 11794-7025, New York, USA

    Carmen Tornos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bell-McGuinn, K.M., Leitao, M.M. (2011). Surface Epithelial Tumors: Clinical Introduction. In: Soslow, R., Tornos, C. (eds) Diagnostic Pathology of Ovarian Tumors. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-9751-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9751-7_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-9750-0

  • Online ISBN: 978-1-4419-9751-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation